POSIFLEX-GROUP
24.5.2019 03:02:05 CEST | Business Wire | Press release
For the Computex 2019 show, The Posiflex Group is featuring leading solution technology from the family of brands as a fully Serviced IoT Ecosystem. Solution end points include:
- Connected Modular Kiosks, POS Terminals, and Digital Signage solutions from Posiflex and KIOSK Information Systems
- Smart Medical Displays with gesture controls from Portwell
- Connected Gaming Solutions with Player Tracking Technology from Portwell subsidiary, Ganlot
The booth display is based on common field service endpoints represented in a European Manor Destination Resort setting. Field solutions for an array of vertical market applications include QSR ordering, cinema ticketing, fashion retail customer loyalty, interactive signage, hotel / medical center check-in and bill pay, as well as casino gaming technology.
This year, in addition to their renowned POS product suite, Posiflex will be featuring newly introduced Modular Kiosk platforms (co-designed by KIOSK and Posiflex), which are configure-to-order standard models available through Global Distribution Channel. The Modular Kiosks leverage The Posiflex Group’s in-house supply chain capabilities, including self-sourced computing and peripherals like scanners, printers, and PCAP displays as well as optional transaction components common across multiple configurations and use cases – ultimately, delivering shorter lead times and reduced cost with longevity support.
Owen Chen, CEO of Posiflex notes, “Our brand family portfolio has grown to include a highly strategic blend of POS , Kiosk , and Embedded Computing Technology. This year at Computex, The Group will proudly feature the addition of a powerful Remote Management System (RMS).” This robust tool, as showcased in a Command Center, enables real-time alerting and dashboard management of any smart device within the Field Edge Network, including kiosks, POS terminals, transaction peripherals, computers, gateways, and more. This RMS solution adds actionable IoT insights to realize the best day-to-day network up-time while reducing field service costs. Mr. Chen adds, “IoT communication capabilities have profoundly elevated Field Management standards and The Posiflex Group is very pleased to offer this state-of-the-art RMS tool, coupled with its versatile Modular Kiosk offerings for the Global Channel Market.”
Real-time RMS component-level alerting puts actions in motion that prevent costly down-time. Acting on routine alerts (low-paper printer sensor / bill acceptor capacity limit sensor) stimulate daily maintenance actions that prevent outages from happening in the first place. IoT component and sensor alert monitoring provide real-time automated insights organizing Service Personnel to resolve preventative maintenance issues - while enabling customer-facing associates to focus on more pressing and profitable sales demands.
Within the Group, KIOSK Information Systems has a strong track record of providing comprehensive Field Managed Services (FMS) to an elite fleet of high-volume and mission-critical clients. This service bundle consists of:
- Remote Management System, paired with:
- Turnkey Managed Services, with knowledgeable Information Technology professionals to perform proactive remote monitoring and remediation.
- Partner-enabled Global Field Services, including Site Survey and Installation, Advanced Exchange Warranty and Field Service deployment.
KIOSK will champion the gradual global implementation of the FMS model, adding IoT and Managed Service insights across Posiflex Group’s regional service capabilities.
To learn more, please join the Team at:
Exhibition Hall: 4F, Taipei Nangang Exhibition Center Hall Two
Booth Number: R0314
About Posiflex Group:
Posiflex has designed and manufactured world-class POS solutions for more than 30 years. Since 2016, the company has acquired KIOSK and Portwell, further expanding into self-service and embedded PC offerings. The global Posiflex group is in place to provide world-class B2B Serviced IoT solutions.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190523005015/en/
Contact:
Posiflex Group Press Contact: Brad Chou, marketing@posiflex.com.tw
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom